Scholarlink

Purpose <p>To evaluate the safety and efficacy of ophthalmic nerve stimulation (ONS), combined with ascorbic acid (AA) in the treatment of retinitis pigmentosa (RP).</p> Methods <p>Forty participants with RP were enrolled in a prospective open-label single-armed intervention. Patients with non-syndromic RP; aged ≥ 4 years, with BCVA ≥ 20/400 were included. All participants were treated with bilateral ONS sessions combined with intravenous administration of AA for two weeks. The primary efficiency endpoint was the change in scotopic vision at 6 months, assessed using 10-item, 100-point, Low Luminance Questionnaire (LLQ-10). The secondary efficiency points included BCVA and contrast sensitivity. Rod responders were defined by ≥ 25 points increment of LLQ-10 score at 6 months’ visit.</p> Results <p>Ocular neuromodulation therapy significantly improved low luminance vision, BCVA, and contrast sensitivity in patients with RP (<i>p ≤ 0.05</i>). At 6-month visits, 60% of patients were identified as rod responders. The mean change in LLQ-10 score was (46.35 ± 16.81 point) in rod responders versus (4.9 ± 7.6 point) in non-responders (<i>p &lt; 0.0001</i>). A clinically significant improvement of BCVA (≥ 0.2 logMAR unit) and contrast sensitivity (≥ 0.3 log unit) were demonstrated in 50% of the right eyes of rod responders.</p> Conclusion <p>Ocular neuromodulation significantly improved night vision, BCVA, and contrast sensitivity. Determinants of rod responders include the duration of night blindness, stage of the disease, and thickness of ganglion cell layer at baseline. Two therapeutic scenarios were recognized; an early disease-modifying intervention that restores night vision and a late cone rescue intervention that improves/maintains central vision.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ocular neuromodulation as a novel treatment for retinitis pigmentosa: identifying rod responders and predictors of visual improvement

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Ismail M Musallam

摘要

Purpose

To evaluate the safety and efficacy of ophthalmic nerve stimulation (ONS), combined with ascorbic acid (AA) in the treatment of retinitis pigmentosa (RP).

Methods

Forty participants with RP were enrolled in a prospective open-label single-armed intervention. Patients with non-syndromic RP; aged ≥ 4 years, with BCVA ≥ 20/400 were included. All participants were treated with bilateral ONS sessions combined with intravenous administration of AA for two weeks. The primary efficiency endpoint was the change in scotopic vision at 6 months, assessed using 10-item, 100-point, Low Luminance Questionnaire (LLQ-10). The secondary efficiency points included BCVA and contrast sensitivity. Rod responders were defined by ≥ 25 points increment of LLQ-10 score at 6 months’ visit.

Results

Ocular neuromodulation therapy significantly improved low luminance vision, BCVA, and contrast sensitivity in patients with RP (p ≤ 0.05). At 6-month visits, 60% of patients were identified as rod responders. The mean change in LLQ-10 score was (46.35 ± 16.81 point) in rod responders versus (4.9 ± 7.6 point) in non-responders (p < 0.0001). A clinically significant improvement of BCVA (≥ 0.2 logMAR unit) and contrast sensitivity (≥ 0.3 log unit) were demonstrated in 50% of the right eyes of rod responders.

Conclusion

Ocular neuromodulation significantly improved night vision, BCVA, and contrast sensitivity. Determinants of rod responders include the duration of night blindness, stage of the disease, and thickness of ganglion cell layer at baseline. Two therapeutic scenarios were recognized; an early disease-modifying intervention that restores night vision and a late cone rescue intervention that improves/maintains central vision.